Insight into miRNAs related with glucometabolic disorder - 16/02/19
, Bi-wei Zhu, Hua-ying An, Bo Zheng, Sheng-bo Xu, Jia-chen Sun, Peng-chao Sun, Wen Zhang, Jia Wang, Jia-ying Liu, Ya-qian FanBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | This article clarifies the manifestations of glucometabolic disorders in the body. |
• | This article reveals the role of miRNAs in glucometabolic disorders. |
• | This paper reviews the most recent advances in some typical miRNAs related to glucometabolic disorders. |
• | This paper presents the problems faced by the use of miRNAs in the treatment of glucometabolic disorders. |
• | This paper presents the solutions that can be taken to provide reference for the application of miRNAs in the future. |
Abstract |
A microRNA (miRNA) is a single-stranded, small and non-coding RNA molecule that contains 20–25 nucleotides. More than 2000 miRNAs have been identified in human genes since the first miRNA was discovered in Caenorhabditis elegans in the early 1990s. miRNAs play a crucial role in various biological processes by regulating gene expression through post-transcriptional mechanisms. The alterations of their levels are associated with various diseases, such as glucometabolic disorder and lipid metabolism disorder. In recent years, miRNAs have been proved to be involved in regulating the functions of pancreatic β-cells, insulin resistance and other biological behaviors related to glucometabolic disorder and the pathogenesis of diabetes mellitus (DM).
This review summarized specific miRNAs, including miRNA-375 (miR-375), miRNA-155 (miR-155), miRNA-21 (miR-21), miRNA-33 (miR-33), the let-7 family and some other miRNAs related to glucometabolic regulation, introduced the obstacles and challenges in miRNA therapy, and discussed the prospect of new treatment methods for glucometabolic disorder.
Le texte complet de cet article est disponible en PDF.Keywords : microRNA, Hyperglycemia, Diabetes, Glucose metabolism, miRNA-375, miRNA-21, miRNA-33, miRNA-155, let-7, Metabolic syndrome
Plan
Vol 111
P. 657-665 - mars 2019 Retour au numéro
Article précédent
- Presepsin: A promising biomarker for the detection of bacterial infections
- Mohammad Yousef Memar, Hossein Bannazadeh Baghi
- Applications of nanotechnology in drug delivery to the central nervous system
- Majid Saeedi, Masoumeh Eslamifar, Khadijeh Khezri, Solmaz Maleki Dizaj
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?